BioNTech and Pfizer initiate rolling submission to European Medicines Agency (EMA) for SARS-CoV-2 vaccine candidate BNT162b2

The EMA’s decision to start a rolling review follows encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers production of neutralising antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2.

Source:

Biospace Inc.